Introduction
Encapsulating peritoneal sclerosis (EPS) is an uncommon but serious complication of long-term peritoneal dialysis (PD). It is has been associated with high morbidity and mortality since it was first described in 1980 [1] . Currently, the largest reported experience has been from Japan where patient survival on PD is longer than elsewhere [2] . A 4-year prospective multicentre study of almost 2000 patients in Japan showed strikingly that incidence and mortality correlated with PD duration, ranging from an incidence of 0.7-17% from 3 to >15 years PD duration, and an associated mortality from 17.2 to 100%.
There is little literature about the clinical course of EPS. Most centres will see only a few patients; the largest welldescribed cohorts have been from Japan consisting of 124 patients [3] and 48 patients [2] . An earlier Australian multicentre retrospective study reported on 54 cases [4] . All showed that development of EPS correlated with PD duration, high membrane permeability [5] and loss of ultrafiltration. Recurrent peritonitis and use of chlorhexidine were also suggested to be risk factors [6] . Evidence-based treatment is lacking and there is no uniformly accepted management. Steroids have been shown to be beneficial especially in the early 'inflammatory' phase of the disease process that precedes the diffuse scarring of the peritoneum [2] . Use of immunosuppressive treatment has been reported in small patient series [4, 7] and case reports [8, 9] and has been suggested to be beneficial. Tamoxifen has also been used in some cases [10] [11] [12] [13] . Early surgery with bowel resection and anastomosis had a high mortality rate; surgical management now mainly focuses on enterolysis with some centres showing good results [13] [14] [15] . However, this procedure is still associated with significant mortality and has a high recurrence rate [16] .
There is concern that more cases of EPS are being diagnosed in the UK, particularly after transplantation [17, 18] . As a result, the Pan-Thames Audit Group, which encompasses all the renal units in London and South-East England, decided to carry out a survey of their patients with a diagnosis of EPS. The aims of the study were to determine how clinicians were making the diagnosis, its clinical features, predictors and management. We hoped to collect data on a large cohort of patients and gain data on incidence and outcome.
Methods
Physicians in charge of the 11 PD units in the Pan-Thames region were contacted in February 2007 and asked to obtain information on patients who had been diagnosed with EPS since 1997. The diagnosis of EPS was made by clinicians from the various centres based on clinic-pathological criteria as outlined by International Society for Peritoneal Dialysis ad hoc committee on ultrafiltration management in PD [19] . The peritoneal biopsy material would have been reviewed by pathologists at the various centres. Previously described changes consistent with EPS including interstitial fibrosis, fibrin deposition and microvascular sclerosis [19, 20] would have been used to confirm the diagnosis of EPS. Data from each patient were entered on to a proforma; this included date of diagnosis, duration of PD, frequency and type of peritonitis, clinical features, investigations, management and outcome. Details on dialysis adequacy, ultrafiltration, residual renal function and membrane transport status were also requested. Data sheets were compiled and information was entered into a standard database program, Microsoft Access (Microsoft). A further questionnaire was sent out in March 2008 to determine status (treatment modality or date of death) of patients who were alive at the time of the initial survey. 
Statistical analysis
Continuous data are expressed as mean ± SE. Median with range is used where distribution was not normal. Survival is displayed using KaplanMeier curves formed using a prism. Statistical analysis has not been performed to compare groups due to low numbers and the heterogeneous nature of the groups.
Results
There were 111 cases of EPS identified from 11 units; the earliest case was from 1997 and 77 cases were diagnosed since 2004. A variable number of cases were reported from individual units (Table 1) . Mortality from each unit is also shown in Table 1 .
Demographics
The mean age was 52.0 ± 14.3 years with a range of 21-79 years; 52 were male and 59 were female. The cause of kidney disease was reported as chronic glomerulonephritis in 24 patients (22%), diabetic nephropathy in 18 (16%), hypertension in 12 (11%), polycystic kidney disease in 8 (7%), reflux in 9 (7%) and other causes in 40 patients (37%).
PD details
The mean duration of PD was 83.7 ± 3.9 months, with a range of 8-243 months ( Figure 1 ). Seventy-nine (71%) patients diagnosed with EPS had been on PD for more than 5 years. PD details are shown in Table 2 . Peritonitis history was available in 100 patients ( Table 2 ). Ten patients had no peritonitis, 28 had one previous episode, 29 had two previous episodes and 33 had three or more previous episodes. Seventeen patients developed EPS within 
Modality at diagnosis of EPS
Forty-six patients were on PD at the time of diagnosis, 51 patients were on HD and 14 had a functioning transplant. Peritonitis was the cause of transfer onto HD in 20 patients and ultrafiltration failure in 17 patients, the remainder were not specified. The average time on HD prior to diagnosis of EPS was 5.5 months (range 0.5-37 months), with 38 (75%) patients having the diagnosis within 6 months. Twenty-nine of the 51 patients transferred to HD developed EPS within 3 months; peritonitis accounted for 17 of these cases. The average time post-transplant before diagnosis of EPS was 5.4 months (range 1-19 months).
Membrane permeability and ultrafiltration
Data on the last peritoneal equilibration test (PET) were available for 63 patients ( Table 2 ). The length of time between the test and the development of EPS was not known. The mean D/P was high at 0.84 ± 0.02 (range 0.54-0.99) though seven patients were in the low average range (0.5-0.65). The last D/P was available on 14 of the 17 patients who had ultrafiltration failure and were transferred onto HD prior to diagnosis of EPS; 13 out of the 14 were high transporters. Ultrafiltration details were available for 68 patients; the mean ultrafiltration was 936 ± 70.4 ml (range 100-3300 ml). Urine output was available in 14 patients (range 0-1500 ml); 11 patients had residual renal function with urine output in the range of 200-1500 ml.
Clinical features
All patients had symptoms suggestive of EPS to prompt investigation to confirm diagnosis. Abdominal pain and vomiting were the commonest symptoms, being reported in 74 (67%) and 66 (59%) patients, respectively. A large proportion, 57 (51%) patients, had both symptoms and a clinical diagnosis of bowel obstruction was made in 37 (33%) of these patients. Ascites was reported in 43 (39%) patients and weight loss was noted as a significant problem in 21 (20%) patients. Other symptoms reported were diarrhoea, abdominal distention and loss of appetite.
Making the diagnosis
CT scanning was the commonest mode of investigation that led to the confirmation of a diagnosis of EPS. Scan results were available in 96 patients. Common CT findings reported to support the diagnosis of EPS were peritoneal thickening (n = 60, 58%), matted bowel (n = 30, 31%) and calcification (n = 27, 28%). Other findings were dilated small bowel and ascites. The CT scan was reported as normal in 14 patients; of these, eight went on to have a laparotomy and six had their diagnosis made entirely on clinical symptoms. Laparotomy was performed in 47 patients in total; 16 of these had a peritoneal biopsy with histological features reported as consistent with a diagnosis of EPS. Biopsy material was not available. Barium meal and follow-through were performed in 10 patients with 9 showing slow transit.
Treatment
A total 105 patients survived for further management. We cannot comment on the timing and varying doses of drug treatment used in these patients. Drug treatment consisting of tamoxifen, immunosuppression and steroids were used in 54 patients in total; the remaining 46 patients had no specified treatment. Five patients underwent surgical treatment with adhesionolysis, two of who had various drug treatments as well, one as a transplant regime (indicated on Table 3 , excluded from analysis). Of the five patients who underwent adhesionolysis, four received parenteral nutritional support. A further 30 patients also received parenteral nutrition (PN). The various drug regimes used are shown in Table 3 . Tamoxifen was given to 17 patients as a single agent and in combination with other drugs to 14 patients. Steroids were used in 29 patients; this included 4 patients as a single agent and 13 patients in association with a transplantation regime. Immunosuppression drugs were used in 26 patients, 21 associated with transplantation and 5 as an additional treatment with steroids. The immunosuppression drugs used were azathioprine, cyclosporin (CsA), tacrolimus, mycophenolate mofetil (MMF) and sirolimus.
Overall survival (Figures 1 and 2) One-year overall survival was 56%. The overall median survival was 14 months (range 0-119). Six patients died around the time of diagnosis. The overall mortality was 53% with 59 deaths in the group of 111 patients. Mortality increased with length of time on PD being 42% at <3 years, 32% at 3-4 years, 61% at 5-6 years, 54% at 7-8 years, 75% at 9-10 years and 59% at >10 years. The median time to death from diagnosis was 7 months (range 0-64) ( Figure 2) ; Table 3 eight people died within a month of diagnosis and remaining deaths occurred within 30 months, apart from one at 64 months.
Modality and survival (Figure 3)
Fourteen patients had functioning transplants at the time of diagnosis and a further eight patients received a transplant after diagnosis. Patients with functioning transplants prior to a diagnosis of EPS had a median survival of 14 months (range 2-101). The eight patients transplanted after diagnosis had a mean age of 43.8 ± 5 years, with a mean PD duration of 45.0 ± 11 months and a median survival of 34.5 months (range 9-108). Overall survival in transplanted patients appeared to be better (median 20.5 months, n = 22, range 2-108) compared to patients who were maintained on HD (median 13.5 months, n = 74, range 1-119). Of the 46 patients on PD at diagnosis, 1 died around diagnosis, 33 patients were maintained on HD and 5 were eventually transplanted. The seven patients remaining on PD had a median survival of 19 months (range 1-26).
Drug treatment and survival (Figure 4)
Survival time was reviewed in various groups of patients who had medical treatment. This excluded patients who died around diagnosis, underwent adhesionolysis or were transplanted. The median survival for patients not given any specific drug treatment was 13 months (range 1-84, n = 46). The median survival of patients given tamoxifen was 15 months (range 1-58, n = 17), those given steroids ± immunosuppression drugs was 7 months (range 1-119, n = 8) and those give tamoxifen plus steroids ± immunosuppression was 14 months (range 6-38, n = 8).
Parenteral nutrition (Figure 5)
The median survival of the 39 patients who received PN was 10 months (range 0-101, n = 30), compared to 15 months (range 0-119, n = 53) for those maintained on oral nutrition. There were 20 deaths in the PN group with a median time to death of 5 months (range 0-16) compared to 28 deaths with a median time to death of 9 months (range 0-64) in those remaining on oral nutrition. Patients who received PN, therefore, had a worse initial mortality. 
Surgical adhesionolysis
Five patients underwent surgical adhesionolysis, four received PN support. Two died at 6 and 21 months (patient without PN), 3 are alive at 25 and 59 months (additional steroid and tamoxifen treatment) and 89 months (transplanted, steroid, MMF, tacrolimus treatment). Three patients had other surgical procedures with PN support; jejeunostomy, bowel resection and ileal-transverse colon bypass; survival was 9 (deceased), 2 (deceased) and 17 months (alive) respectively.
Discussion
EPS is mostly diagnosed by the presence of clinical symptoms of bowel obstruction, weight loss and in some cases, ascites. Confirmation of the diagnosis can be made using radiological investigations such as CT scanning, ultrasound, barium studies and/or finding the characteristic cocoon at surgery [19] . The current understanding is that EPS mostly occurs in patients on long-term PD and is related to changes in the peritoneal membrane, that peritonitis is sometimes involved in its development and that many cases occur after discontinuation of PD [21] .
Most information about EPS comes from Japan where, for various reasons, there are more long-term PD patients than elsewhere. This survey of EPS by the Pan-Thames Audit Group provides information about a large case series in the UK. It is limited by being retrospective and relies on clinical recall. Not all cases were reported, e.g. one unit had lost all the notes of their deceased patients because of a flood in the basement where the notes were stored. In particular, there is limited information about PD details for individual patients. The strength of this study lies in the information about mode of diagnosis and outcome with regard to treatment and mortality.
As in previous studies, EPS is predominantly a complication of long-term PD with 75 (71%) patients having been on PD for more than 5 years, though there were 12 (11%) patients who had been on PD for less than 3 years. As in the prospective study of Kawanishi [2] , mortality increased with duration on PD from 33% at 3-5 years to 63% for patients on PD for more than 10 years. The majority of patients (68%) were diagnosed after 2004, but as this is a retrospective study relying on physician recall, we cannot conclude that this represents an increase in the incidence of EPS. There did not appear to be any difference in outcome in patients diagnosed before or after 2004. There was variation in the frequency of EPS in different centres; this can be partly explained by the age of the centre with newer centres having fewer long-term PD patients. Increased physician awareness of EPS will also prompt more diagnostic investigations and therefore more cases being detected.
Not surprisingly, the symptoms of EPS were predominantly nausea, vomiting, abdominal distension and pain. CT scanning was generally the investigation of choice. The decision to undertake surgical exploration and biopsy was centre dependent; 25 patients had a laparotomy even though they had features suggestive of EPS on CT scans. Of note, eight patients with CT scans reported as normal went on to have their diagnosis made at laparotomy. This may represent the lack of knowledge by local radiologists about EPS or may suggest that some cases may occur without any obvious CT findings. There were six patients whose diagnoses were made by their clinicians on entirely clinical grounds. We cannot postulate on circumstances that may have caused this; the patient may have been too unwell or management may not have been felt to have altered due to the result of the scan. Either way, both patients who had a normal CT scan and those who did not have a scan appear to have had just as poor survival as those with CT findings of EPS.
The majority of patients (58%) developed EPS after discontinuation of PD. This is well recognized in the Japanese literature [2] with 68% in Kawanishi's prospective study developing EPS on stopping PD. This may represent previous peritoneal injury that becomes more progressive due to failure to remove pro-fibrotic cytokines by PD effluent [21] . The development of EPS shortly after transplantation is of particular interest in that these patients will have been on potent immunosuppression drugs. Some patients may have had subclinical EPS associated with poor ultrafiltration and weight loss while still on PD. This does pose a significant management dilemma with regard to transferring modality in patients who may be detected early.
Although data about the actual PD was limited, our study does confirm that EPS predominantly occurs in patients with the high membrane transport status and in those with poor ultrafiltration. It is important to note, though, that finding the low membrane transport status on a peritoneal equilibration test or having significant ultrafiltration do not preclude the diagnosis. Almost all the patients who had ultrafiltration failure prior to a diagnosis of EPS were high transporters. This goes against conventional teaching that ultrafiltration failure in EPS is associated with low transport status. Changes in the membrane transport status and/or ultrafiltration rates may be more informative as predictors, but this information is not available from this study. Peritonitis data were available for almost all patients (103/111). As in other studies, peritonitis did precede EPS in some patients, with 17 developing the syndrome within 3 months of transferring to HD because of peritonitis. A history of peritonitis, however, is not a prerequisite for developing EPS; 38 patients had no or only one previous episode. This is not surprising as peritonitis is a major cause of technique failure in PD so patients with a high peritonitis rate would not remain on PD for long term. Other series also report that EPS is associated with peritonitis in some but not all patients [3] .
The principal advantage of collecting data on this large cohort of patients with EPS relates to survival and the effects of treatment in comparison with the many anecdotal reports based on small numbers or even single patients. Such reports often suggest beneficial effects of corticosteroids [2] , immunosuppressive drugs such as CsA, azathioprine [4, 7] , tacrolimus, sirolimus [8] , MMF [9] and tamoxifen [10, 11, 12, 13] . Physicians, of course, do not write papers on individual patients who do not respond to such therapies and there could also be a bias towards selecting fitter patients for immunosuppression therapy. Overall, 53% patients died and the median survival was 14 months. Death occurred early in the course of the disease with the median time to death being 7 months. There are numerous treatment strategies utilized by the various centres and information from the data is difficult to interpret. Numbers in our groups were small and treatment was very varied. Furthermore, we do not have information on when and for how long treatment would have been used in particular. However, we could not see better survival between patients getting no drug treatment and the groups being given tamoxifen and/or immunosuppression (including steroids). Interestingly, a recent study in rats has shown that CsA had a profibrotic action in the peritoneum suggesting that it may in fact contribute to the pathogenesis of EPS posttransplantation [22] . All of the 21 transplant patients in our cohort had a calcineurin inhibitor as part of their treatment regime; two patients were switched to sirolimus monotherapy after the diagnosis. The group would have a strong selection bias towards better survival, and treatment subgroups were too small, so any negating effect from the continued use of calcineurin inhibitors would be difficult to observe.
Nutritional support is vital for the management of these patients. About one-third of the patients in this study were on PN. There was no information about the nature of oral nutritional supplements, nutritional status of patients or why patients were selected for PN. Median time to death was shorter in this group compared to patients maintained on oral nutrition. This could be due to many factors such as infectious complications of administering PN, failure to provide adequate nutrition in HD patients with fluid restrictions and/or selecting sicker malnourished patients for PN.
The modality outcome appears to have a significant impact on survival. Patients who are transplanted, both before and after the diagnosis of EPS have the best survival. A strong positive selection bias would favour better survival in this group, but it is useful to highlight that EPS should not preclude patients from transplantation, and all patients should be optimized to receive a transplant as this provides the best survival outcome. The observation that patients on long-term PD can develop EPS shortly after transplantation while on potent immunosuppression treatment may support the data that such treatment does not have a role in the management of patients with EPS.
This study confirms the previous correlation of incidence and mortality with prolonged PD duration. Diagnosis is based on clinical symptoms, supported mostly by CT findings. Available drug treatments and parenteral nutritional support do not appear to offer a clear survival advantage, but PN may be indicated in more severely affected patients with intestinal failure. Overall, long-term survival is possible, particularly after transplantation. With the presence of increasing numbers of patients with prolonged PD, prospective studies are required to investigate predictive factors and any benefit from treatment.
